PACAP glycosides promote cell outgrowth in vitro and reduce infarct size after stroke in a preclinical model

• Published in: Neuroscience letters 2024-07, Vol.836, p.137883, Article 137883
• Main Authors: Bernard, Kelsey, Dickson, Denali, Anglin, Bobbi L., Leandro Heien, M., Polt, Robin, Morrison, Helena W., Falk, Torsten
• Format: Article
• Language: English
• Subjects: Glycopeptides; Ischemia; Mouse tMCAO model; PC12 cells; Pituitary adenylate cyclase activating polypeptide
• ISSN: 0304-3940; 1872-7972; 1872-7972
• DOI: 10.1016/j.neulet.2024.137883

Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) is a pleiotropic peptide known to promote many beneficial processes following neural damage and cell death after stroke. Despite PACAP’s known neurotrophic and anti-inflammatory properties, it has not realized its translational potential due to a poor pharmacokinetic profile (non-linear PK/PD), and limited Blood-Brain Barrier Penetration (BBB) permeability. We have previously shown that glycosylation of PACAP increases stability and enhances BBB penetration. In addition, our prior studies showed reduced neuronal cell death and neuroinflammation in models of Parkinson’s disease and Traumatic Brain Injury (TBI). In this study we show that a PACAP(1−27) glucoside retains the known neurotrophic activity of native PACAP(1−27)in vitro and a 5-day daily treatment regimen (100 nM) leads to neurite-like extensions in PC12 cells. In addition, we show that intraperitoneal injection of a PACAP(1−27) lactoside (10 mg/kg) with improved BBB-penetration, given 1-hour after reperfusion in a Transient Middle Cerebral Artery Occlusion (tMCAO) mouse model, reduces the infarct size after the ischemic injury in males significantly by ∼ 36 %, and the data suggest a dose-dependency. In conclusion, our data support further development of PACAP glycopeptides as promising novel drug candidates for the treatment of stroke, an area with an urgent clinical need.